16 patents
Utility
De-immunized Factor VIII Molecule and Pharmaceutical Compositions Comprising the Same
11 Jan 24
The present invention relates to the field of therapeutic proteins, in particular, to recombinant coagulation factors.
Karina Winterling, Steffen Kistner, Jens Daufenbach, Annie de Groot, William Martin, Christopher Ungerer
Filed: 11 Apr 19
Utility
Method and Kit for Testing Immunomodulatory Potency of Immunoglobulin Compositions for Treatment of COVID-19
14 Dec 23
The present invention relates to the field of immunotherapeutics, in particular to a method for characterization and/or quality control of immunotherapeutics.
Fabian BOHLÄNDER, Stefanie FAUST
Filed: 18 Nov 21
Utility
Methods of treating viral infections by administering an antibody preparation comprising IGG, IGA and IGM
10 Oct 23
An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies.
Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
Filed: 5 Feb 21
Utility
Treatment of Severe Community Acquired Pneumonia
3 Aug 23
The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).
Patrick Langohr, Andrea Wartenberg-Demand, Ulrike Wippermann, Benjamin Daelken
Filed: 2 Dec 22
Utility
Protein Comprising at Least One Regulatory T Cell Activating Epitope
25 May 23
The present invention relates to the field of immunology, in particular, to the field of modulation of immune responses, in particular, suppression of immune responses and/or induction of tolerance.
Steffen KISTNER, Jens DAUFENBACH, Christopher UNGERER, Peter HERBENER, Holger WALLMEIER
Filed: 26 Mar 21
Utility
Method for Manufacturing a Fibrinogen Preparation
26 Jan 23
A method for manufacturing a fibrinogen preparation from a fibrinogen containing source derived from blood plasma includes providing a liquid phase containing plasmatic fibrinogen; contacting the liquid phase with a cation exchange chromatography material under conditions resulting in binding of fibrinogen, wherein the liquid phase has a pH in the range of pH 5.6 to pH 7.0 which is near or above the pl of fibrinogen; optionally washing unbound compounds from the cation exchange chromatography material; and eluting the fibrinogen from the cation exchange material.
Vera Ott, Wolfgang Möller, Oliver Maneg
Filed: 8 Dec 20
Utility
Treatment of severe community acquired pneumonia
6 Dec 22
The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).
Patrick Langohr, Andrea Wartenberg-Demand, Ulrike Wippermann, Benjamin Daelken
Filed: 15 Jan 21
Utility
Single Chain Factor VIII Molecule
18 Aug 22
The present invention relates to a recombinant Factor VIII protein comprising, in a single chain, a heavy chain portion comprising an A1 and an A2 domain and a light chain portion comprising an A3, C1 and C2 domain of Factor VIII, wherein the B-domain is partially deleted in two deletions, the first leading to the presence of a defined processing sequence cleavable by thrombin, and the second leading to absence of the furin cleavage recognition site at position R1664-R1667.
Steffen Kistner, Christopher Ungerer, Jens Daufenbach, Peter Herbener
Filed: 8 May 20
Utility
Process for Preparing Immunoglobulin Compositions
21 Jul 22
A process for the preparation of pharmaceutically acceptable immunoglobulin compositions from plasma-derived immunoglobulin fractions which allows the parallel preparation of immunoglobulin compositions enriched in IgG, IgM and IgA.
Oliver Maneg, Achim Hannappel, Alexander Moehlenkamp-Roettger, Wolfgang Moeller, Dieter Rudnick
Filed: 8 Apr 22
Utility
Method and Kit for Testing Potency of Immunoglobulin Compositions
21 Jul 22
The present invention relates to the field of immunotherapeutics.
Katharina Heim, Marcus Gutscher
Filed: 5 Jun 20
Utility
Process for preparing immunoglobulin compositions
10 May 22
A process for the preparation of pharmaceutically acceptable immunoglobulin compositions from plasma-derived immunoglobulin fractions which allows the parallel preparation of immunoglobulin compositions enriched in IgG, IgM and IgA.
Oliver Maneg, Achim Hannappel, Alexander Moehlenkamp-Roettger, Wolfgang Moeller, Dieter Rudnick
Filed: 26 Jul 17
Utility
Antibody Preparations
17 Jun 21
An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies.
Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
Filed: 5 Feb 21
Utility
Treatment of Severe Community Acquired Pneumonia
3 Jun 21
The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).
Patrick Langohr, Andrea Wartenberg-Demand, Ulrike Wippermann, Benjamin Daelken
Filed: 15 Jan 21
Utility
IgG, IgA and IgM antibody preparations, method of making and method of use in treatment
23 Mar 21
An antibody preparation suitable for intravenous administration in humans includes IgG, IgA and at least 5% IgM antibodies by weight of the total amount of antibodies.
Wolfgang Möller, Dieter Rudnick, Oliver Maneg, Michael Rodemer, Matthias Germer, Veit Braun
Filed: 9 Jul 18
Utility
Treatment of severe community acquired pneumonia
16 Feb 21
The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).
Patrick Langohr, Andrea Wartenberg-Demand, Ulrike Wippermann, Benjamin Daelken
Filed: 10 Feb 20
Utility
Treatment of Severe Community Acquired Pneumonia
26 Aug 20
The present invention provides for a new therapeutic tools capable of treating infectious diseases, in particular, a new pharmaceutical composition comprising an IgM-enriched immunoglobulin preparation for use in the adjunctive treatment of severe Community Acquired Pneumonia (sCAP).
Patrick Langohr, Andrea Wartenberg-Demand, Ulrike Wippermann, Benjamin Daelken
Filed: 9 Feb 20
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first